ANTLER trial shows positive initial data for CB-010 anti-CD19 allogeneic CAR T-cell therapy

CAR T Vision Coalition launches with goal of doubling patients treated with the curative potential of CAR T-cell therapy by 2030

On May 30, an international coalition announced the launch of CAR T Vision, a coalition that aims to unite stakeholders around the shared ambition that every eligible patient should have the opportunity for cure with CAR T-cell therapy.

May 30, 2025

Vol.51 No.21

In Brief

KU Cancer Center breaks ground for new complex

The University of Kansas Cancer Center broke ground on the future site of a new complex on May 22 that will bring research and patient care into one area for the first time in KU Cancer Center’s history.

May 30, 2025

Vol.51 No.21

Clinical Roundup

Efti + radiotherapy + Keytruda regimen meets primary endpoint in phase II study in soft tissue sarcoma

Investigator-initiated EFTISARC-NEO phase II trial evaluating eftilagimod alfa (efti) with radiotherapy plus Keytruda (pembrolizumab) in the neoadjuvant setting for resectable soft tissue sarcoma has met its primary endpoint.

May 30, 2025

Vol.51 No.21

Regulatory News

ODAC marathon: Committee charges through a pileup of clinical questions in a two-day, four-application session

In two back-to-back, all-day meetings, the FDA Oncologic Drugs Advisory Committee considered four thorny applications that the agency appeared to have been saving up as a result of the pause in activity that followed President Trump’s return to office.

FDA grants accelerated approval to avutometinib + defactinib for KRAS-mutated recurrent low-grade serous ovarian cancer

FDA has approved Avmapki Fakzynja Co-Pack (avutometinib capsules; defactinib tablets) for the treatment of adult patients with KRAS-mutated recurrent low-grade serous ovarian cancer who received prior systemic therapy. Avmapki Fakzynja Co-Pack is the first and only FDA-approved medicine for this disease.

May 23, 2025

Vol.51 No.20

In Brief

Intermountain Health to expand stem cell collection for CAR-T cell therapy, bringing procedure to southern Utah

Intermountain Health is now offering a national expansion of CAR-T cell therapy, bringing cancer care closer to patients in southern Utah and Nevada.

May 16, 2025

Vol.51 No.19

ANTLER trial shows positive initial data for CB-010 anti-CD19 allogeneic CAR T-cell therapy

YOU MAY BE INTERESTED IN

CAR T Vision Coalition launches with goal of doubling patients treated with the curative potential of CAR T-cell therapy by 2030

KU Cancer Center breaks ground for new complex

Efti + radiotherapy + Keytruda regimen meets primary endpoint in phase II study in soft tissue sarcoma

ODAC marathon: Committee charges through a pileup of clinical questions in a two-day, four-application session

FDA grants accelerated approval to avutometinib + defactinib for KRAS-mutated recurrent low-grade serous ovarian cancer

Intermountain Health to expand stem cell collection for CAR-T cell therapy, bringing procedure to southern Utah

Renew today!

Subscriber content

Never miss an issue!

Login